Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af mezagitamab hos voksne med primær IgA nefropati nyre tilstand

3. november 2026 opdateret af: Takeda

En fase 3-multicenter, randomiseret, dobbeltblind, placebo-kontrolleret forsøg for at evaluere effektivitet og sikkerhed for mezagitamab (TAK-079) i undersøgelsesdeltagere med primær IGA-nefropati i kombination med stabil baggrundsterapi

Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo.

Participants will be placed in 1 of the 2 treatment groups; the main group and the open-label group. In the main group, participants will be placed by chance in either the mezagitamab or placebo treatment group at a 2:1 ratio. This means that out of 3 participants, 2 will receive mezagitamab and 1 will receive placebo. Participants can be in the study for 2 years (104 weeks). Participants will receive study treatment for about half a year (22 weeks) and then be observed for the remainder of the study (about 1.5 years). During observation, participants will continue to have check-ups about every month.

In the open-label group, a small number of participants who either have lower levels of protein in their urine or have kidneys that do not filter the blood well, will receive mezagitamab treatment. This will include participants who have previously received mezagitamab in another study, TAK-079-1006. Every participant will receive mezagitamab in the same way as those in the main group receiving mezagitamab.

During the study, participants will visit their study clinic several times.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

347

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Ciudad Autonoma Buenos Aires, Argentina, 1280
        • Rekruttering
        • Hospital Britanico de Buenos Aires
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Hernan Trimarchi Jurado
      • Córdoba, Argentina, X5016
        • Rekruttering
        • Clinica Privada Velez Sarsfield
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Rafael Alberto Maldonado
    • Buenos Aires
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1425AGC
        • Rekruttering
        • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Alejandra Smuclir Quevedo
    • La Plata
      • Buenos Aires, La Plata, Argentina, 1902
        • Rekruttering
        • Framingham Centro Medico
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Martin Mamberti
    • New South Wales
      • Liverpool, New South Wales, Australien
        • Rekruttering
        • South Western Sydney Local Health District - University of New South Wales - Liverpool Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Beata Zahorowska
    • Queensland
      • Milton, Queensland, Australien
        • Rekruttering
        • Core Research Group
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • David Colquhoun
    • Victoria
      • Box Hill, Victoria, Australien, 3128
        • Rekruttering
        • Eastern Health
        • Ledende efterforsker:
          • Darren Lee
        • Kontakt:
          • Site Contact
      • Clayton, Victoria, Australien
        • Rekruttering
        • Monash Heath - Monash University - Monash Medical Centre
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Jessica Ryan
      • St Albans, Victoria, Australien, 3021
        • Rekruttering
        • Western Health Sunshine Hospital
        • Ledende efterforsker:
          • Eugenia Pedagogos
        • Kontakt:
          • Site Contact
    • Alberta
      • Calgary, Alberta, Canada, T2R 0X7
        • Rekruttering
        • Sheldon M. Chumir Health Centre
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Louis Girard
    • Ontario
      • London, Ontario, Canada, N6A5A5
        • Rekruttering
        • London Health Sciences Centre
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Matthew Weir
      • Toronto, Ontario, Canada, M4G 3E8
        • Rekruttering
        • Sunnybrook Health Sciences Centre
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Michelle Hladunewich
      • Canterbury, Det Forenede Kongerige, CT1 3PA
        • Rekruttering
        • Kent & Canterbury Hospital, Canterbury
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Tharindra Somasinghe
      • Hull, Det Forenede Kongerige
        • Rekruttering
        • Hull University Teaching Hospitals NHS Trust
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Sunil Bhandari
      • Leicester, Det Forenede Kongerige
        • Rekruttering
        • Leicester General Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Chee Kay Cheung
      • London, Det Forenede Kongerige, WC2R 2LS
        • Rekruttering
        • King's College Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Sapna Shah
      • London, Det Forenede Kongerige, SW17 0QT
        • Rekruttering
        • St George's University Hospitals NHS Foundation Trust
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Richard Hull
      • Nottingham, Det Forenede Kongerige
        • Rekruttering
        • Nottingham University Hospitals NHS Trust - City Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Matthew Hall
      • Preston, Det Forenede Kongerige, PR29HT
        • Rekruttering
        • Lancashire Teaching Hospital NHS Foundation Trust
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Arvind Ponnusamy
      • Sheffield, Det Forenede Kongerige
        • Rekruttering
        • Northern General Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Arif Khwaja
    • Greater London
      • London, Greater London, Det Forenede Kongerige, SE1 9RT
        • Rekruttering
        • Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Dimitrios-Anestis Moutzouris
    • United Kingdom of Great Britain and Northern Ireland
      • Birmingham, United Kingdom of Great Britain and Northern Ireland, Det Forenede Kongerige
        • Rekruttering
        • Birmingham Heartlands Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Bamidele Tokunbo Ajayi
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35233-2110
        • Rekruttering
        • UAB Nephrology Research Clinic at Paula Building
        • Ledende efterforsker:
          • Dana Rizk
        • Kontakt:
          • Site Contact
      • Montgomery, Alabama, Forenede Stater, 36117
        • Rekruttering
        • DCR Montgomery
        • Ledende efterforsker:
          • Vinayak Ramanath
        • Kontakt:
          • Site Contact
    • Arizona
      • Surprise, Arizona, Forenede Stater, 85374
        • Rekruttering
        • Panoramic Health - Southwest Kidney Institute, PLC
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Minesh Rajpal
    • California
      • Fremont, California, Forenede Stater, 94538
        • Rekruttering
        • Panoramic Health - West Coast Kidney Institute (Fremont)
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Varun Chawla
      • Los Angeles, California, Forenede Stater, 90022
        • Rekruttering
        • Academic Medical Research Institute
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Mohammed El-Shahwy
      • Los Angeles, California, Forenede Stater, 90095
        • Rekruttering
        • UCLA University of California Los Angeles
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Anjay Rastogi
      • Orange, California, Forenede Stater, 92868-3201
        • Rekruttering
        • University of California Irvine
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Ramy Hanna
      • San Francisco, California, Forenede Stater, 94118
        • Rekruttering
        • Kaiser Permanente San Francisco Medical Center
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Ali Poyan-Mehr
    • Florida
      • Jacksonville, Florida, Forenede Stater, 32250
        • Rekruttering
        • Panoramic Health - Florida Kidney Physicians, LLC (Jacksonville)
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Prasanth Krish
      • Lauderdale Lakes, Florida, Forenede Stater, 33313-1607
        • Rekruttering
        • South Florida Research Institute
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Edouard Martin
      • Melbourne, Florida, Forenede Stater, 32901
        • Rekruttering
        • Panoramic Health - Florida Kidney Physicians, LLC (Melbourne)
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Claus Peter Spies
      • Miami, Florida, Forenede Stater, 33127
        • Rekruttering
        • Bioresearch Partners
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Jose Miguel Cardona-Guzman
      • Miami, Florida, Forenede Stater, 33176
        • Rekruttering
        • Total Health and Research Center (THRC)
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Jeffrey Maldonado
      • Orlando, Florida, Forenede Stater, 32806
        • Rekruttering
        • CTR Oakwater, LLC
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Arvind Madan
      • Pembroke Pines, Florida, Forenede Stater, 33029
        • Rekruttering
        • Bioresearch Partners
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Max Benjamin
      • Riverview, Florida, Forenede Stater, 33578
        • Rekruttering
        • Panoramic Health - Florida Kidney Physicians, LLC (Tampa)
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Amit Augustine Johnsingh
      • Sanford, Florida, Forenede Stater, 32771
        • Rekruttering
        • Infigo Clinical Research LLC
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Sayed Husain
    • Georgia
      • Columbus, Georgia, Forenede Stater, 31904
        • Rekruttering
        • DCR Columbus
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Tamorie Smith
      • East Point, Georgia, Forenede Stater, 30344
        • Rekruttering
        • Panoramic Health - Southeast Kidney Associates
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Charmaine Ifeoma Emelife
    • Idaho
      • Boise, Idaho, Forenede Stater, 83706
        • Rekruttering
        • CARE Institute - Boise Kidney
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Arnold Silva
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Rekruttering
        • Northwestern University
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Yonatan Peleg
      • Rockford, Illinois, Forenede Stater, 61107
        • Rekruttering
        • Panoramic Health - RNA of Rockford, LLC dba Rockford Nephrology Associates
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Syed Mustafa Ahmed
    • Louisiana
      • Shreveport, Louisiana, Forenede Stater, 71101
        • Rekruttering
        • Northwest Louisiana Nephrology
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Marwan Kaskas
    • Michigan
      • Lansing, Michigan, Forenede Stater, 48911
        • Rekruttering
        • Ingham Nephrology & Hypertension, P.C.
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Brian Cousino
      • Pontiac, Michigan, Forenede Stater, 48341
        • Rekruttering
        • Elixia MKC
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Fahd Al-Saghir
      • Saint Joseph, Michigan, Forenede Stater, 49085
        • Rekruttering
        • Panoramic Health - Lake Michigan Nephrology, PLC
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Oliver Chambers Songlingco
    • Minnesota
      • Edina, Minnesota, Forenede Stater, 55435
        • Rekruttering
        • DCR Edina
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Shannon Doyle
    • Missouri
      • City of Saint Peters, Missouri, Forenede Stater, 63376
        • Rekruttering
        • Elixia MNA
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Gary Singer
      • Kansas City, Missouri, Forenede Stater, 64111
        • Rekruttering
        • Clinical Research Consultants a JCCT Company
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Ahmed Awad
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87109
        • Rekruttering
        • Renal Medicine Associates - Frenova F1
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Jayant Kumar
    • North Carolina
      • Winston-Salem, North Carolina, Forenede Stater, 27103
        • Rekruttering
        • Brookview Hills Research Associates, LLC
        • Ledende efterforsker:
          • Nicholas McLean
        • Kontakt:
          • Site Contact
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45212
        • Rekruttering
        • Panoramic Health - Kidney and Hypertension Center
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • James Davis
    • Pennsylvania
      • Media, Pennsylvania, Forenede Stater, 19063
        • Rekruttering
        • Panoramic Health - Clinical Renal Associates, Ltd.
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Nathan Okechukwu
      • Philadelphia, Pennsylvania, Forenede Stater, 19107
        • Rekruttering
        • Thomas Jefferson University
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Charlene Deng
    • Rhode Island
      • East Providence, Rhode Island, Forenede Stater, 02914
        • Rekruttering
        • Panoramic Health - Nephrology Associates, Inc.
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Larissa Kruger Gomes
    • Texas
      • Dallas, Texas, Forenede Stater, 75230
        • Rekruttering
        • Dallas Renal Group
        • Ledende efterforsker:
          • Irfan Agha
        • Kontakt:
          • Site Contact
      • El Paso, Texas, Forenede Stater, 79902
        • Rekruttering
        • DCR - El Paso
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Simon Rodriguez
      • Houston, Texas, Forenede Stater, 77054
        • Rekruttering
        • Provecta Research Network
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Sreedhar Mandayam
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • Houston Methodist Research Institute - Department of Medicine
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Peter Nguyen
      • Katy, Texas, Forenede Stater, 77450
        • Rekruttering
        • Nephrology Associates of Houston PLLC
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Syed Hussain
      • San Antonio, Texas, Forenede Stater, 78215
        • Rekruttering
        • Sun Research Institute
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Reyes Leonel
      • San Antonio, Texas, Forenede Stater, 78251
        • Rekruttering
        • DCR San Antonio
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Tahira Alves
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84115
        • Rekruttering
        • Utah Kidney Research Institute
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Sanjiv Anand
    • Virginia
      • Arlington, Virginia, Forenede Stater, 22205
        • Rekruttering
        • Panoramic Health - Virginia Nephrology Group
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Renuka Sothinathan
    • West Virginia
      • Morgantown, West Virginia, Forenede Stater, 26506
        • Rekruttering
        • West Virginia University
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Bethany Pellegrino
      • Bordeaux, Frankrig, 33076
        • Rekruttering
        • CHU Bordeaux, CHU Pellegrin
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Claire Rigothier
      • Limoges, Frankrig, 87042
        • Rekruttering
        • CHU Limoges Service de Nephrology
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Fatouma Toure
      • Montpellier, Frankrig, 34090
        • Rekruttering
        • Centre Hospitalier Universitaire de Montpellier (CHU Montpellier) - Hopital Lapeyronie
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Moglie Le Quintrec
      • Nantes, Frankrig, 44093
        • Rekruttering
        • CHU de Nantes
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Simon Ville
      • Paris, Frankrig, 75020
        • Rekruttering
        • Hospital Tenon
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Khalil Karoui
    • Paris
      • Créteil, Paris, Frankrig, 94000
        • Rekruttering
        • Hospital Henri Mondor
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Vincent Audard
      • Leiden, Holland, 2333 ZA
        • Rekruttering
        • Leids Universitair Medisch Center
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Joris Rotmans
      • Nieuwegein, Holland, 3435CM
        • Rekruttering
        • Sint Antonius ziekenhuis Utrecht/Nieuwegein
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Gurbey Ocak
      • Nijmegen, Holland, 6525 GA
        • Rekruttering
        • Radboud Universitair Medisch Centrum
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Raphael Duivenvoorden
      • Utrecht, Holland, 3584 CX
        • Rekruttering
        • UMC Utrecht
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Sabine Meijvis
    • North Holland
      • Amsterdam, North Holland, Holland, 1105 AZ
        • Rekruttering
        • Amsterdam UMC - Locatie AMC (Academisch Medisch Centrum)
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Marc Hilhorst
    • Hong Kong Island
      • Hong Kong, Hong Kong Island, Hong Kong
        • Rekruttering
        • The University of Hong Kong - Department of Medicine
        • Ledende efterforsker:
          • Sydney Chi Wai Tang
        • Kontakt:
          • Site Contact
      • Bologna, Italien, 40138
        • Rekruttering
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Gaetano La Manna
      • Brescia, Italien, 25124
        • Rekruttering
        • ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Federica Mescia
      • Genoa, Italien, 16132
        • Rekruttering
        • IRCCS Ospedale Policlinico San Martino
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Francesca Viazzi
      • Messina, Italien, 98122
        • Rekruttering
        • Az Ospedaliera Universitaria Policlinico G Martino
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Domenico Santoro
      • Milan, Italien, 20100
        • Rekruttering
        • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Giuseppe Castellano
      • Pavia, Italien, 27100
        • Rekruttering
        • Istituto Maugeri IRCCS Pavia
        • Ledende efterforsker:
          • Ciro Esposito
        • Kontakt:
          • Site Contact
      • Piacenza, Italien, 29121
        • Rekruttering
        • Azienda Unita Sanitaria Locale Piacenza (AUSL) Ospedale "Guglielmo da Saliceto
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Roberto Scarpioni
      • Torino, Italien, 10126
        • Rekruttering
        • AOU Citta della Salute e della Scienza di Torino
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Luigi Biancone
    • Aichi-ken
      • Kasugai-Shi, Aichi-ken, Japan, 486-8510
        • Rekruttering
        • Kasugai Municipal Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Yosuke Saka
      • Nagoya, Aichi-ken, Japan, 466-8650
        • Rekruttering
        • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Shoji Saito
      • Toyoake-shi, Aichi-ken, Japan, 470-1192
        • Rekruttering
        • Fujita Health University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Naotake Tsuboi
    • Chiba
      • Chiba, Chiba, Japan, 260-8712
        • Rekruttering
        • National Hospital Organization Chiba Medical Center Chibahigashi National Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Takehiko Kawaguchi
    • Fukuoka
      • Fukuoka, Fukuoka, Japan, 812-8582
        • Rekruttering
        • Kyushu University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Toshiaki Nakano
    • Fukushima
      • Fukushima, Fukushima, Japan, 960-1295
        • Rekruttering
        • Fukushima Medical University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Kazama Junichiro
    • Hiroshima
      • Hiroshima, Hiroshima, Japan, 734-8551
        • Rekruttering
        • Hiroshima University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Takao Masaki
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 060-8648
        • Rekruttering
        • Hokkaido University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Daigo Nakazawa
    • Kanagawa
      • Kamakura-shi, Kanagawa, Japan, 247-8533
        • Rekruttering
        • Shonan Kamakura General Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Hidaka Sumi
      • Kawasaki-shi, Kanagawa, Japan, 213-8587
        • Rekruttering
        • Toranomon Hospital Kajigaya
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Naoki Sawa
      • Yokohama, Kanagawa, Japan, 236-0004
        • Rekruttering
        • Yokohama City University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Kouichi Tamura
    • Miyagi
      • Sendai, Miyagi, Japan, 981-3281
        • Rekruttering
        • Japan Community Health care Organization Sendai Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Santoru Sanada
    • Nara
      • Kashihara-shi, Nara, Japan, 634-8522
        • Rekruttering
        • Nara Medical University Hospital
        • Ledende efterforsker:
          • Kazuhiko Tsuruya
        • Kontakt:
          • Site Contact
      • Nara, Nara, Japan, 630-8581
        • Rekruttering
        • Nara Prefecture General Medical Center
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Hideo Tsushima
    • Oita Prefecture
      • Yufu-shi, Oita Prefecture, Japan, 879-5593
        • Rekruttering
        • Oita University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Fukuda Akihiro
    • Osaka
      • Osaka, Osaka, Japan, 530-8480
        • Rekruttering
        • Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofuka
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Takeshi Matsubara
    • Saitama
      • Koshigaya-shi, Saitama, Japan, 343-8555
        • Rekruttering
        • Dokkyo Medical University Saitama Medical Center
        • Ledende efterforsker:
          • Tetsuro Takeda
        • Kontakt:
          • Site Contact
    • Tokyo
      • Bunkyo-ku, Tokyo, Japan, 113-8431
        • Rekruttering
        • Juntendo University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Yusuke Suzuki
      • Shinjuku-Ku, Tokyo, Japan, 160-0023
        • Rekruttering
        • Tokyo Medical University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Takahito Moriyama
    • Yamanashi
      • Chuo-shi, Yamanashi, Japan, 409-3898
        • Rekruttering
        • University of Yamanashi Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Ayumu Nakashima
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100034
        • Rekruttering
        • Peking University First Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Jicheng Lv
      • Changping, Beijing Municipality, Kina, 102218
        • Rekruttering
        • Beijing Tsinghua Changgung Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Yuehong Li
    • Fujian
      • Xiamen, Fujian, Kina, 361004
        • Rekruttering
        • Zhongshan Hospital Xiamen University
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Bo Xu
    • Guangdong
      • Guangdong, Guangdong, Kina, Guangdong
        • Rekruttering
        • The First Affiliated Hospital of Sun Yat-sen University
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Wei Chen
      • Guangzhou, Guangdong, Kina, 510080
        • Rekruttering
        • Guangdong General Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Zhiming Ye
      • Shenzhen, Guangdong, Kina, 518000
        • Rekruttering
        • Peking University Shenzhen Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Zu-Ying Xiong
    • Hunan
      • Changsha, Hunan, Kina, 410013
        • Rekruttering
        • The Third Xiangya Hospital of Central South University Yuelu District
        • Ledende efterforsker:
          • Hao Zhang
        • Kontakt:
          • Site Contact
    • Inner Mongolia
      • Baotou, Inner Mongolia, Kina, 14010
        • Rekruttering
        • The First Affiliated Hospital of Baotou Medical College
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Zengyan Li
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210009
        • Rekruttering
        • Zhongda Hospital Southeast University
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Liu Bicheng
      • Nantong, Jiangsu, Kina, 226001
        • Rekruttering
        • Affiliated Hospital of Nantong University
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Xinzhong Huang
      • Wuxi, Jiangsu, Kina, 214023
        • Rekruttering
        • Wuxi People's Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Liang Wang
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330006
        • Rekruttering
        • The First Affiliated Hospital of Nanchang University
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Yan Yan
    • Shandong
      • Jinan, Shandong, Kina, 250012
        • Rekruttering
        • Shandong University - Qilu Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Xiang-Dong Yang
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200000
        • Rekruttering
        • Shanghai Jiao Tong University School of Medicine (SJTUSM) - Renji Hospital - Eastern Branch
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Leyi Gu
      • Shanghai, Shanghai Municipality, Kina, 200025
        • Rekruttering
        • Ruijin Hospital of Shanghai Jiaotong University School of Medicine
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Jingyuan Xie
    • Sichuan
      • Chengdu, Sichuan, Kina, 610000
        • Rekruttering
        • West China Hospital Sichuan University
        • Ledende efterforsker:
          • Ping Fu
        • Kontakt:
          • Site Contact
      • Chengdu, Sichuan, Kina, 610072
        • Rekruttering
        • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Guisen Li
      • Yibin, Sichuan, Kina, 644099
        • Rekruttering
        • The Second People's Hospital of Yibin
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Deqiong Xie
    • Xiangzhou District, Guangdong Province
      • Zhuhai, Xiangzhou District, Guangdong Province, Kina, 519000
        • Rekruttering
        • Fifth Affiliated Hospital Sun Yat-Sen University
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Cheng Wang
    • Zhejiang
      • Hangzhou, Zhejiang, Kina
        • Rekruttering
        • The Second Affiliated Hospital, Zhejiang University, School of Medicine
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Kunling Ma
      • Ningbo, Zhejiang, Kina, 315010
        • Rekruttering
        • The First Affiliated Hospital of Ningbo University
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Xueyan Bian
      • Kuala Lumpur, Malaysia, 50603
        • Rekruttering
        • Universiti Malaya Medical Centre (UMMC)
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Soo Kun Lim
    • Kuala Lumpur
      • Kuala Lumpur, Kuala Lumpur, Malaysia, 56000
        • Rekruttering
        • Universiti Kebangsaan Malaysia (UKM) - Medical Centre (Pusat Perubatan) (Hospital Canselor Tuanku Muhriz (HCTM))
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Lydia Kamaruzaman
    • Pahang
      • Kuantan, Pahang, Malaysia, 25100
        • Rekruttering
        • Hospital Tengku Ampuan Afzan
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Fariz Safhan Mohamad Nor
    • Perak
      • Taiping, Perak, Malaysia, 34000
        • Rekruttering
        • Hospital Taiping
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Kok Seng Teng
    • Selangor
      • Kajang, Selangor, Malaysia, 43000
        • Rekruttering
        • Hospital Sultan Idris Shah Serdang (Hospital Serdang)
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Li Lian Tay
      • Subang Jaya, Selangor, Malaysia, 47500
        • Rekruttering
        • Sunway Medical Centre (SMC)
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Rosnawati Yahya
      • Bergen, Norge, 5021
        • Rekruttering
        • Haukeland Universitetssjukehus
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Thomas Knoop
      • Grålum, Norge, 1714
        • Rekruttering
        • Sykehuset Ostfold
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Dumitrescu Ioana-Elena
      • Stavanger, Norge
        • Rekruttering
        • Stavanger Universitetssjukehus - Helse Stavanger HF
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Goransson Lasse
      • Trondheim, Norge, 7030
        • Rekruttering
        • Universitetssykehuset I Trondheim - St. Olavs Hospital - Nevroklinikken
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Yngvar Haaskjold
    • Akershus
      • Lorenskog, Akershus, Norge, 1478
        • Rekruttering
        • Akershus University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Bartlomiej Witczak
    • Vestfold
      • Tønsberg, Vestfold, Norge
        • Rekruttering
        • Sykehuset I Vestfold
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Kjellevold Stig Arne
      • Gmina Świecie, Polen, 86-100
        • Rekruttering
        • Nowy Szpital Sp Zo.o
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Andrzej Brymora
      • Krakow, Polen, 31-559
        • Rekruttering
        • SCM Sp. z o.o.
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Dariusz Aksamit
      • Lodz, Polen
        • Rekruttering
        • Indywidualna Specjalistyczna Praktyka Lekarska
        • Ledende efterforsker:
          • Michal Nowicki
        • Kontakt:
          • Site Contact
      • Wroclaw, Polen, 50-981
        • Rekruttering
        • 4th Military Clinical hospital /Polyclinic SP ZOZ
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Magdalena Krajewska
      • Zurich, Schweiz, 8091
        • Rekruttering
        • University Hospital Zurich
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Britta George
      • Singapore, Singapore
        • Rekruttering
        • National University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Boon Wee Teo
      • Singapore, Singapore, 169608
        • Rekruttering
        • Singapore General Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Jason Choo
      • Singapore, Singapore, 308433
        • Rekruttering
        • Tan Tock Seng Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • See Cheng Yeo
      • Ljubljana, Slovenien, 1000
        • Rekruttering
        • University Medical Centre Ljubljana
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Andreja Ales Rigler
      • Maribor, Slovenien
        • Rekruttering
        • University Clinical Centre Maribor
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Sebastjan Bevc
      • Barcelona, Spanien, 8035
        • Rekruttering
        • Hospital Universitari Vall d'Hebron
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Irene Agraz Pamplona
      • Barcelona, Spanien, 8003
        • Rekruttering
        • Hospital del Mar
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Eva Rodriguez Garcia
      • Madrid, Spanien, 28027
        • Rekruttering
        • Universidad de Navarra - Clinica Universidad de Navarra
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Jose Maria Mora Gutierrez
      • Madrid, Spanien, 28040
        • Rekruttering
        • Fundacion Jimenez Diaz
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Roberto Scarpioni
      • Seville, Spanien, 41013
        • Rekruttering
        • Hospital Universitario Virgen del Rocio - PPDS
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Manuel Lopez Mendoza
    • Barcelona
      • Badalona, Barcelona, Spanien, 8915
        • Rekruttering
        • Hospital Universitari Germans Trias i Pujol
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Iara Karlla Da Silva Santos
    • Bizkaia
      • Barakaldo, Bizkaia, Spanien, 48903
        • Rekruttering
        • Hospital Universitario de Cruces
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Laura Bueno Lopez
    • Navarre
      • Pamplona, Navarre, Spanien, 31008
        • Rekruttering
        • Universidad de Navarra - Clinica Universidad de Navarra
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Jose Maria Mora Gutierrez
      • Linköping, Sverige
        • Rekruttering
        • Renal Medicine Linkoping University/ Linkoping University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Annette Bruchfeld
      • Seoul, Sydkorea, 3722
        • Rekruttering
        • Severance Hospital, Yonsei University Health System
        • Ledende efterforsker:
          • Seung Hyeok Han
        • Kontakt:
          • Site Contact
      • Seoul, Sydkorea, 3080
        • Rekruttering
        • Seoul National University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Dong Ki Kim
      • Seoul, Sydkorea, 7061
        • Rekruttering
        • Seoul National University Boramae Medical Center
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Jung Pyo Lee
    • Gyeonggi-do
      • Yongin-si, Gyeonggi-do, Sydkorea, 16995
        • Rekruttering
        • Yongin Severance Hospital, Yonsei University Health System
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Young Su Joo
    • Gyeonggido
      • Suwon, Gyeonggido, Sydkorea, 16499
        • Rekruttering
        • Ajou University Hospital-Primary Research Location
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Inwhee Park
    • Seongnam
      • Seongnam-si, Seongnam, Sydkorea, 13620
        • Rekruttering
        • Seoul National University Bundang Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Ho-Jun Chin
      • Kaohsiung City, Taiwan, 807
        • Rekruttering
        • Kaohsiung Medical University - Chung-Ho Memorial Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Yi Wen Chiu
      • New Taipei City, Taiwan
        • Rekruttering
        • Taipei Medical University Shuang Ho Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Mai-Szu Wu
      • Taichung, Taiwan, 40705
        • Rekruttering
        • Taichung Veterans General Hospital
        • Ledende efterforsker:
          • Ming-Ju Wu
        • Kontakt:
          • Site Contact
      • Taichung, Taiwan
        • Rekruttering
        • China Medical University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Ping-Chin Lai
      • Zhongzheng, Taiwan, 100
        • Rekruttering
        • National Taiwan University Hospital
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Jenq-Wen Huang
      • Olomouc, Tjekkiet, 779 00
        • Rekruttering
        • Fakultni nemocnice Olomouc
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Karel Krejci
      • Prague, Tjekkiet
        • Rekruttering
        • First Faculty of Medicine Charles University
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Vladimir Tesar
    • Moravskoslezsk Kraj
      • Nový Jičín, Moravskoslezsk Kraj, Tjekkiet, 741 01
        • Rekruttering
        • Nemocnice AGEL Novy Jicin a.s
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Vaclava Honova
      • Kocaeli, Tyrkiet (Türkiye)
        • Rekruttering
        • Kocaeli Universitesi Tip Fakultesi Arastirma ve Uygulama Hastanesi
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Necmi Eren
    • Battalgazi
      • Malatya, Battalgazi, Tyrkiet (Türkiye), 44280
        • Rekruttering
        • Turgut Ozal Medical Center
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Ozkan Ulutas
    • Gaziantep
      • Şahinbey, Gaziantep, Tyrkiet (Türkiye), 27310
        • Rekruttering
        • Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Fatih Mehmet Erdur
    • Istanbul
      • Fatih, Istanbul, Tyrkiet (Türkiye), 34098
        • Rekruttering
        • Istanbul Universitesi Cerrahpasa Tip Fakultesi
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Nurhan Seyahi
    • Melikgazi
      • Kayseri, Melikgazi, Tyrkiet (Türkiye), 38039
        • Rekruttering
        • Erciyes University
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Bulent Tokgoz
    • Onikisubat
      • Kahramanmaraş, Onikisubat, Tyrkiet (Türkiye), 46040
        • Rekruttering
        • Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Avsar Mah
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Orcum Altunoren
    • Selcuklu
      • Konya, Selcuklu, Tyrkiet (Türkiye), 42280
        • Rekruttering
        • Necmettin Erbakan University
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Kultigin Turkmen
      • Mainz, Tyskland, 55131
        • Rekruttering
        • Universitaetsmedizin der Johannes - Gutenberg Universitaet Mainz
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Julia Weinmann-Manke
    • North Rhine-Westphalia
      • Aachen, North Rhine-Westphalia, Tyskland, 52074
        • Rekruttering
        • Uniklinik RWTH Aachen
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Claudia Seikrit
    • Thuringia
      • Jena, Thuringia, Tyskland, 7747
        • Rekruttering
        • Universitaetsklinikum Jena
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Martin Busch
      • Budapest, Ungarn, 1083
        • Rekruttering
        • Semmelweis Egyetem - Belgyogyaszati es Onkologiai Klinika (I.sz. Belgyogyaszati Klinika)
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Akos Petho
      • Linz, Østrig, 4040
        • Rekruttering
        • Johannes Kepler Universitat Linz, Universitatsklinik fur Innere 2
        • Kontakt:
          • Site Contact
        • Ledende efterforsker:
          • Alexander Moschen
      • Vienna, Østrig, 1090
        • Rekruttering
        • Medizinische Universitat Wien (Medical University of Vienna - Austria)
        • Ledende efterforsker:
          • Rainer Oberbauer
        • Kontakt:
          • Site Contact

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

  • Inclusion Criteria:

To be eligible to participate in this trial, participants must meet all the following criteria:

  1. Either UPCR greater than or equal to (≥) 0.8 gram per gram (g/g) or urine protein excretion (UPE) ≥1 grams per day (g/day), calculated from at least one 24-hour urine collection during the screening period (or pre-screening, if applicable) (only applicable for the main trial).

  2. eGFR greater than (>)30 milliliters per minute per 1.73 meter square (mL/min/1.73m^2) at screening based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (only applicable for the main trial).

  3. No prior exposure to anti- cluster of differentiation 38 (CD38) therapy period (except for open-label cohort participants meeting Inclusion Criterion No. 10.a).

  4. The participant is aged ≥ 18 years or the local legal age as applicable.

  5. The participant (and the participant's legally acceptable representative, as applicable per local regulations or determination) has provided informed consent (that is, in writing, documented via a signed and dated informed consent form [ICF]) and any required privacy authorization before the initiation of any clinical trial procedures.

  6. Diagnosis of primary immunoglobulin A nephropathy (IgAN) supported by a renal biopsy report that is dated more recently than 10 years before the signing of the informed consent for the clinical trial. The redacted report must be made available for review. A renal biopsy must be performed during screening for participants without a biopsy report within 10 years.

  7. Participants must be on stable renin-angiotensin-aldosterone system (RAAS) inhibitor therapy with an angiotensin-converting enzyme inhibitor (ACE-I) and/or angiotensin receptor blocker (ARB) or endothelin receptor antagonist (ERA) or mineralocorticoid receptor antagonist (MRA) agent for at least 12 weeks before signing the ICF with dosing at the maximally tolerated or labeled dose as determined by the investigator, with the intent to continue stable dosing during the clinical trial. Those intolerant of RAAS inhibitor therapy are potentially eligible after consultation with the medical monitor. Intolerance is defined as a documented side effect causing discontinuation of the therapy.

  8. Resting blood pressure less than or equal to (≤)150 millimeters of mercury (mmHg) systolic and ≤100 mmHg diastolic.

  9. Female participants of childbearing potential who are not pregnant during screening (confirmed by negative serum human chorionic gonadotropin [hCG]) and on Visit 1 before first dose of trial intervention (confirmed by negative urine pregnancy test).

  10. Any one of the following (only applicable for participants in the open-label cohort):

    1. Participants in Trial TAK-079-1006 who completed the Week 96 visit or the retreatment period with either UPCR >0.5 g/g or UPE >0.5 g/d calculated from a 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR >30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.

    2. UPCR <0.8 g/g and UPE ≥0.75 and <1.0 g/day, by 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR > 30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.

    3. UPCR ≥ 0.8 g/g or UPE ≥ 1.0 g/d by 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR ≥25 and ≤30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.

      • Exclusion Criteria:

A participant who meets any of the following criteria will be excluded from participation in this trial:

  1. Kidney biopsy exhibiting significant concomitant renal disease other than IgAN (for example, diabetic nephropathy, lupus nephritis, minimal change disease).

  2. Secondary IgAN (such as with significant liver disease, inflammatory bowel disease, and seronegative spondyloarthropathies), and immunoglobulin A (IgA) vasculitis.

  3. Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR within 3 months before the signing of the ICF).

  4. Diagnosis of nephrotic syndrome defined as 24-hour proteinuria >3.5 g/day and hypoalbuminemia (<3.0 grams per deciliter [g/dL]) with or without peripheral edema.

  5. Renal or other organ transplantation prior to or expected during the clinical trial.

  6. Treatment with oral immunosuppressive agents (including cyclophosphamide, mycophenolate mofetil, cyclosporine, azathioprine, calcineurin inhibitors) or biologic therapy for immunomodulation (including immunomodulatory monoclonal or polyclonal antibodies) within 6 months (both B-cell and non-B-cell directed agents) before signing of the ICF.

  7. If the participant has received anti-CD20 treatment, the participant is excluded if either of the following apply:

    1. The last dose was received within 6 months before the signing of the ICF.
    2. The last dose was received between 6 and 12 months before the signing of the ICF and the participant has a CD19+ count below the lower limit of normal.

    Note: Participants who have received the last dose of anti-CD20 treatment >12 months before the signing of the ICF are not excluded from clinical trial participation based on this criterion and are not required to undergo CD19+ testing.

  8. Within 4 months of the screening visit, use of either a) systemic corticosteroids at an average dose of 40 milligrams (mg) prednisone equivalent or higher for more than 14 days or b) oral budesonide delayed release capsules.

  9. The participant has received a live or live-attenuated vaccine within 4 weeks before signing the ICF or has any live or live-attenuated vaccine planned during the clinical trial.

  10. Participation in any other investigational drug trial (including vaccine trial) with receipt of at least 1 dose of investigational drug, or has been exposed to another investigational agent within 4 weeks or 5 half-lives, whichever is longer, before Visit 1.

  11. The participant has active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).

  12. The participant has had any of the following types of infections within the specified timeframes where applicable:

    1. Active bacterial, viral, or fungal infection (except for the common cold and onychomycosis), or any other serious infection within 2 weeks of signing the ICF. Any anti-infective course for infection must be completed at least 2 weeks before Visit 1.
    2. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) infection within 4 weeks of signing the ICF.
    3. Opportunistic infection or treatment for an opportunistic infection less than or equal to (≤)12 weeks before signing the ICF.
    4. Active tuberculosis (TB), any history of prior active TB, or any signs or symptoms of active TB infection (including but not limited to chronic fever, chronic productive cough, night sweats, weight loss, or malnutrition) as judged by the investigator.
    5. For participants in European Union (EU) member states, positive or 2 indeterminant QuantiFERON results, unless there is documentation of prior complete treatment for latent TB, or participant has initiated prophylaxis based on local guidelines and in consultation with a pulmonology or infectious disease specialist prior to the first administration of IMP.
  13. In the opinion of the investigator, the participant is currently experiencing any medical condition that might interfere with participation in the trial (for example, significant ocular, cardiovascular, pulmonary, hematologic, gastrointestinal, endocrinologic, hepatic, renal, neurologic, malignancy, infectious disease, immunodeficiency, or alcohol and drug abuse), that poses an added risk for the participant or could confound the assessment of trial results.

  14. In the opinion of the investigator, the participant has a serious medical or psychiatric illness that could potentially interfere with the completion of treatment.

  15. The participant has a history of major surgery within 3 months before screening (or longer, at the discretion of the investigator); or, either has a planned tonsillectomy or underwent a tonsillectomy within 6 months before screening.

    Note: Major surgery typically requires at least 1 night in the hospital.

  16. History of malignancy (including myelodysplastic syndrome) within 5 years of signing the ICF, except for adequately treated non-melanoma skin cancer, superficial bladder cancer, and curatively treated cervical carcinoma-in-situ.

  17. The participant has a history of a severe allergic or anaphylactic reaction to recombinant proteins or excipients used in the mezagitamab or placebo formulation.

  18. The participant has (1) been diagnosed with or has suspected chronic obstructive pulmonary disease (COPD) or asthma and (2) has a prebronchodilatory forced expiratory volume in 1 second (FEV1) <50% of predicted normal at screening.

  19. The participant is capable of breastfeeding but does not agree to forego breastfeeding from first dose of investigational medicinal product (IMP) through 30 days after the last dose of IMP.

  20. The participant is an individual with potential for pregnancy but does not agree to use at least 1 form of highly effective contraception and 1 barrier method of contraception (preferably male condom) when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP.

  21. The participant is a sexually active, non-sterilized individual who produces sperm but does not agree to use a barrier method (preferably male condom) combined with at least 1 form of highly effective contraception for any partner(s) with potential for pregnancy when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP.

  22. In the investigator's opinion, the participant (and the participant's legally acceptable representative, if applicable per local regulations or determination) is unwilling and/or unable to understand and fully comply with clinical trial procedures and requirements (including digital tools and applications).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Mezagitamab

Participants will receive mezagitamab injections, subcutaneously (SC), for approximately 22 weeks.

Mezagitamab injections administered SC.

Andre navne:
  • TAK-079
Placebo komparator: Placebo

Participants will receive mezagitamab-matching placebo injections, SC for approximately 22 weeks.

Mezagitamab-matching placebo injections administered SC.

Eksperimentel: Open-label Mezagitamab

Participants will receive mezagitamab injections, SC for approximately 22 weeks.

Mezagitamab injections administered SC.

Andre navne:
  • TAK-079

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from Baseline in Proteinuria at Week 36
Tidsramme: From Baseline to Week 36

Proteinuria will be assessed by urine protein to creatinine ratio (UPCR) calculated from a 24-hour urine collection.

From Baseline to Week 36

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ændring fra baseline i estimeret glomerulær filtreringshastighed (EGFR) i henholdsvis 52 og 104
Tidsramme: Fra baseline til uge 52 og 104
Fra baseline til uge 52 og 104
Time From Baseline to the First Occurrence of Sustained Decline in eGFR of ≥30 Percent (%) From Baseline Over at Least 4 Weeks
Tidsramme: From Baseline to Week 104
From Baseline to Week 104
Percentage of Participants Who Achieve ≥30% Reduction From Baseline in Proteinuria at Week 104
Tidsramme: From Baseline to Week 104
From Baseline to Week 104
The Rate of Change in eGFR From Baseline at Week 104
Tidsramme: From Baseline to Week 104

The rate of change in eGFR from baseline is measured as eGFR total slope.

From Baseline to Week 104
Time from Baseline to the First Occurrence of Any of the Pre-specified Kidney Failure Composite Assessment Criteria
Tidsramme: From Baseline to Week 104

The pre-specified assessment criteria will include: sustained decline in eGFR of ≥30% from baseline over at least 4 weeks; sustained eGFR <15 mL/min/1.73 m^2 over at least 4 weeks; initiation of maintenance dialysis defined as dialysis performed for at least 4 weeks; receipt of kidney transplant; or death from kidney failure. Time from baseline to first occurrence of any of the above assessment criteria would be reported.

From Baseline to Week 104

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Study Director, Takeda

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. juli 2025

Primær færdiggørelse (Anslået)

7. september 2028

Studieafslutning (Anslået)

14. januar 2030

Datoer for studieregistrering

Først indsendt

30. april 2025

Først indsendt, der opfyldte QC-kriterier

30. april 2025

Først opslået (Faktiske)

9. maj 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • TAK-079-3001
  • 2025-520825-19-00 (Ctis)
  • 2025 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD-delingsadgangskriterier

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .